Evidence map›Paper›PMID 36051061›Full record

ArticleEJHaem2022

Outcomes of poor peripheral blood stem cell mobilizers with multiple myeloma at the first mobilization: A multicenter retrospective study in Japan.

Yurie Miyamoto-Nagai, Naoya Mimura, Nobuhiro Tsukada, Nobuyuki Aotsuka, Masaki Ri, Yuna Katsuoka, Toshio Wakayama, Rikio Suzuki, Yoriko Harazaki, Morio Matsumoto and 15 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EJHaem, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 20 institutions in 1 country.

Yurie Miyamoto-NagaiDepartment of Hematology Chiba University Hospital Chiba Japan.ORCID https://orcid.org/0000-0001-8952-8669
Naoya MimuraDepartment of Hematology Chiba University Hospital Chiba Japan.
Nobuhiro TsukadaDivision of Hematology Japanese Red Cross Medical Center Tokyo Japan.
Nobuyuki AotsukaDepartment of Hematology and Oncology Japanese Red Cross Narita Hospital Narita Japan.
Masaki RiDepartment of Hematology and Oncology Nagoya City University Graduate School of Medical Sciences Nagoya Japan.
Yuna KatsuokaDepartment of Hematology National Hospital Organization Sendai Medical Center Sendai Japan.
Toshio WakayamaDepartment of Hematology and Oncology Shimane Prefectural Central Hospital Izumo Japan.
Rikio SuzukiDepartment of Hematology and Oncology, Department of Medicine Tokai University School of Medicine Isehara Japan.
Yoriko HarazakiDepartment of Hematology Miyagi Cancer Center Natori Japan.
Morio MatsumotoDepartment of Hematology National Hospital Organization Shibukawa Medical Center Shibukawa Japan.
Kyoya KumagaiDivision of Hematology-Oncology Chiba Cancer Center Chiba Japan.
Takaaki MiyakeDepartment of Oncology and Hematology Shimane University Hospital Izumo Japan.
Shuji OzakiDepartment of Hematology Tokushima Prefectural Central Hospital Tokushima Japan.ORCID https://orcid.org/0000-0002-9808-0752
Katsuhiro ShonoDepartment of Hematology Chiba Aoba Municipal Hospital Chiba Japan.
Hiroaki TanakaDepartment of Hematology Asahi General Hospital Asahi Japan.
Arika ShimuraDepartment of Hematology and Oncology, Graduate School of Medicine The University of Tokyo Tokyo Japan.
Yoshiaki KurodaDepartment of Hematology National Hospital Organization Hiroshimanishi Medical Center Otake Japan.
Kazutaka SunamiDepartment of Hematology National Hospital Organization Okayama Medical Center Okayama Japan.
Kazuhito SuzukiDepartment Clinical Oncology and Hematology The Jikei University Kashiwa Hospital Kashiwa Japan.
Takeshi YamashitaDepartment of Internal Medicine Keiju Kanazawa Hospital Ishikawa Japan.
Kazuyuki ShimizuDepartment of Hematology/Oncology Higashi Nagoya National Hospital Nagoya Japan.
Hirokazu MurakamiFaculty of Medical Technology and Clinical Engineering Gunma University of Health and Welfare Maebashi Japan.
Masahiro AbeDepartment of Hematology, Endocrinology and Metabolism Tokushima University Graduate School Tokushima Japan.
Chiaki NakasekoDepartment of Hematology International University of Health and Welfare School of Medicine Narita Japan.ORCID https://orcid.org/0000-0003-1175-226X
Emiko SakaidaDepartment of Hematology Chiba University Hospital Chiba Japan.
Chiba University Hospital · JPNational Hospital Organization · JPAsahi General Hospital · JPChiba Aoba Municipal Hospital · JPChiba Cancer Center · JPGunma University of Health and Welfare · JPHigashi Nagoya National Hospital · JPInternational University of Health and Welfare · JPJapanese Red Cross Medical Center · JPJapanese Red Cross Narita Hospital · JPJikei University Kashiwa hospital · JPKanazawa Hospital · JPMiyagi Prefectural Hospital Organization · JPNagoya City University · JPOhnishi Neurological Center · JPSendai Medical Center · JPShimane Prefectural Central Hospital · JPShimane University Hospital · JPTokai University · JPTokushima Prefectural Central Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Autologous stem cell transplantation (ASCT) remains an important therapeutic strategy for multiple myeloma; however, a proportion of patients fail to mobilize a sufficient number of peripheral blood stem cells (PBSCs) to proceed to ASCT. In the present study, we aimed to clarify the characteristics and outcomes of poor mobilizers. Clinical data on poorly mobilized patients who underwent PBSC harvest for almost 10 years were retrospectively collected from 44 institutions in the Japanese Society of Myeloma (JSM). Poor mobilizers were defined as patients with less than 2 × 10

Indexed as

autologous stem cell transplantationMultiple myelomaperipheral blood stem cellspoor mobilizers

Identifiers

PMID36051061
PMCPMC9422024
OpenAlexW4286491565

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.